@article{cb61fe0ff00746cab0c34318c77159d8,
title = "User design and experience preferences in a novel smartphone application for migraine management: A think aloud study of the RELAXaHEAD application",
abstract = "Objective. Scalable nonpharmacologic treatment options are needed for chronic pain conditions. Migraine is an ideal condition to test smartphone-based mind-body interventions (MBIs) because it is a very prevalent, costly, disabling condition. Progressive muscle relaxation (PMR) is a standardized, evidence-based MBI previously adapted for smartphone applications for other conditions. We sought to examine the usability of the RELAXaHEAD application (app), which has a headache diary and PMR capability. Methods. Using the “Think Aloud” approach, we iteratively beta-tested RELAXaHEAD in people with migraine. Individual interviews were conducted, audio-recorded, and transcribed. Using Grounded Theory, we conducted thematic analysis. Participants also were asked Likert scale questions about satisfaction with the app and the PMR. Results. Twelve subjects participated in the study. The mean duration of the interviews (SD, range) was 36 (11, 19–53) minutes. From the interviews, four main themes emerged. People were most interested in app utility/practicality, user interface, app functionality, and the potential utility of the PMR. Participants reported that the daily diary was easy to use (75%), was relevant for tracking headaches (75%), maintained their interest and attention (75%), and was easy to understand (83%). Ninety-two percent of the participants would be happy to use the app again. Participants reported that PMR maintained their interest and attention (75%) and improved their stress and low mood (75%). Conclusions. The RELAXaHEAD app may be acceptable and useful to migraine participants. Future studies will examine the use of the RELAXaHEAD app to deliver PMR to people with migraine in a low-cost, scalable manner.",
keywords = "MHealth, Migraine, Mind Body Intervention, Progressive Muscle Relaxation, Smartphone",
author = "Minen, {Mia T.} and Adama Jalloh and Emma Ortega and Powers, {Scott W.} and Sevick, {Mary Ann} and Lipton, {Richard B.}",
note = "Funding Information: Dr. Mia Minen has a NIH K23 (AT009706-01) and is a recipient of the American Academy of Neurology-American Brain Foundation Practice Research Training Fellowship, which has supported her salary to conduct this research. In addition, this study was supported by a grant from the New York University Clinical Translational Science Institute (NYU CTSI) (UL1TR001445). Funding Information: Dr. Scott Powers has received research funding from the National Institutes of Health (NIH) and from the Migraine Research Foundation. Dr. Richard B. Lipton receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; holds stock options in eNeura Therapeutics and Biohaven Holdings; and serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy{\textquoteright}s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff{\textquoteright}s Headache (8th ed., Oxford Press University, 2009), Wiley, and Informa. Dr. Mary Ann Sevick has funding for her research from the NIH, the Aetna Foundation, and Merck. Funding Information: Funding sources: Dr. Mia Minen has a NIH K23 (AT009706-01) and is a recipient of the American Academy of Neurology-American Brain Foundation Practice Research Training Fellowship, which has supported her salary to conduct this research. In addition, this study was supported by a grant from the New York University Clinical Translational Science Institute (NYU CTSI) (UL1TR001445). Funding Information: Disclosure and conflicts of interest: Dr. Mia Minen receives research funding from the National Institutes of Health, the American Academy of Neurology– American Brain Foundation, the NYU CTSI, the NYU Center for Healthcare Innovation Delivery Services, the International Headache Academy, and the National Multiple Sclerosis Society. Dr. Minen was previously PI of an investigator initiated study with Curelator but that study is no longer taking place. There was no financial relationship that would have occurred if the study had taken place. Ms. Adama Jalloh and Ms. Emma Ortega have no disclosures. Publisher Copyright: {\textcopyright} 2018 American Academy of Pain Medicine. All rights reserved.",
year = "2019",
month = feb,
day = "1",
doi = "10.1093/pm/pny080",
language = "English (US)",
volume = "20",
pages = "369--377",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "2",
}